1 in 7 Caribbean Adults With Breast or Ovarian Cancers Have Actionable Pathogenic Variants
One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.
Rodriguez Relays Insight Into the Integration of Immunotherapy in Lung Cancer
February 18th 2021In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.
Spotlighting Management Strategies Across Sarcoma Subtypes
January 4th 2021Faculty of a recent Institutional Perspectives in Cancer webinar on sarcoma, hosted by Sylvester Comprehensive Cancer Center, share updates in the management of gastrointestinal stromal tumor, epithelioid and synovial sarcoma, and tenosynovial giant cell tumor.
Sarcoma: Chaired by Jonathan Trent, MD, PhD
November 19th 2020Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of sarcoma.
Dr. Mahal on the Prevalence of Prostate Cancer in African American Men
November 2nd 2020Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the prevalence of prostate cancer among African American men.
Dr. Moore on Anticipated Impact of the MIRASOL Trial in Platinum-Resistant Ovarian Cancer
September 2nd 2020Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.